Sign in to follow
Search Results

0 results for 'Novo Nordisk'

You can use to get even better search results
People of the State of New York, by and through Eric T. Schneiderman, Attorney General of the State of New York, Plaintiff-Appellee v. Actavis PLC, Forest Laboratories, LLC, Defendants-Appellants, 14-4624
Publication Date: 2015-06-02
Practice Area: Antitrust
Industry:
Court: U.S. Court of Appeals, Second Circuit
Judge: Before: Walker, Raggi, and Droney, C.JJ.
Attorneys:
For plaintiff: For Plaintiff-Appellee: Barbara D. Underwood, Andrew Kent, Eric J. Stock, Elinor R. Hoffmann, on the brief, Anisha S. Dasgupta, for Eric T. Schneiderman, Attorney General of the State of New York, New York, N.Y.
For defendant: For Defendants-Appellants: Sarah M. Harris, Robert A. DeRise, Arnold & Porter, LLP, Washington, D.C.; George T. Conway III, Wachtell, Lipton, Rosen & Katz, New York, N.Y.; J. Mark Gidley, Peter J. Carney, Claire A. DeLelle, White & Case LLP, Washington, D.C.; Jack E. Pace III, Martin M. Toto, White & Case LLP, New York, N.Y., on the brief, Lisa S. Blatt, Arnold & Porter LLP, Washington, D.C.
Case number: 14‐4624

Cite as: The People v. Actavis PLC, 14‐4624, NYLJ 1202727961229, at *1 (2d Cir., Decided May 22, 20151) 14‐4624p class

May 12, 2015 |

Define Trade Secrets Before and During Litigation

In business as in life, it never hurts to be clear on what each party brings to a relationship and what those things are really worth. A series of decisions in Synygy v. ZS Associates highlight the critical importance of defining an enterprise's trade secret information when using that information to run the business as well as when a dispute breaks out and litigation ensues.
6 minute read
May 12, 2015 | Law.com

Define Trade Secrets Before and During Litigation

In business as in life, it never hurts to be clear on what each party brings to a relationship and what those things are really worth. A series of decisions in highlight the critical importance of defining an enterprise's trade secret information when using that information to run the business as well as when a dispute breaks out and litigation ensues.
6 minute read
Victor M. Serby, Plaintiff v. First Alert, Inc. and BRK Brands, Inc., Defendants, 09-CV-4229
Publication Date: 2015-03-23
Practice Area: Intellectual Property
Industry:
Court: U.S. District Court, Eastern District
Judge: District Judge William Kuntz
Attorneys:
For plaintiff:
For defendant:
Case number: 09-CV-4229

Cite as: Serby v. First Alert, Inc., 09-CV-4229, NYLJ 1202721147840, at *1 (EDNY, Decided March 3, 2015) 09-CV-4229 District Judge William

November 11, 2014 |

Plaintiffs Renew Bid to See Diabetes Drug Reports

More than 540 plaintiffs alleging they developed pancreatic cancer by taking one of four Incretin-based drugs have asked a federal judge to reconsider his ban on discovery into adverse events involving those drugs that were reported to the Food and Drug Administration.
3 minute read
October 08, 2014 |

Largest Law Firms

Largest Law Firms
69 minute read
September 19, 2014 |

Discovery Motion Rejected In Diabetes Drug Case

The federal judge presiding over the multidistrict litigation involving incretin-based therapies has denied a motion to compel discovery about the defendants' analysis of a causal association between the drugs and pancreatic cancer.
2 minute read
The Republic of Iraq, including as Parens Patriae on behalf of the Citizens of the Republic of Iraq, Plaintiff-Appellant v. ABB AG, Defendants-Appellees*, 13-0618
Publication Date: 2014-09-19
Practice Area:
Industry:
Court: U.S. Court of Appeals, Second Circuit
Judge: Before: Kearse, Winter, and Droney, C.JJ.
Attorneys:
For plaintiff:
For defendant:
Case number: 13-0618

Cite as: Iraq v. ABB AG, 13-0618, NYLJ 1202670694614, at *1 (2d Cir., Decided September 18, 2014) 13-0618 Before: Kearse, Winter, and Droney,

September 08, 2014 |

Venable Appeals Win for Generics in Hospira Sedative Fight

Less than three weeks after halting drugmakers Mylan and Par Pharma from selling generic versions of Hospira's blockbuster sedative Precedex, a judge in Baltimore performed an unexpected about-face that allows the generics to resume sales.
3 minute read
August 29, 2014 |

Pharma Companies Oppose Discovery Push in Incretin Litigation

A group of pharmaceutical companies defending their Incretin-based therapies in federal court oppose a motion to compel discovery about adverse events involving their products and reported to the Food and Drug Administration.
2 minute read

TRENDING STORIES

    More from ALM

    More from ALM

    Legal Speak is a weekly podcast that makes sense of what’s happening in the legal industry.

    Resources